SVN-015
| Clinical data | |
|---|---|
| Other names | SVN015 |
| Routes of administration | Unspecified[1] |
| Drug class | Serotonin–dopamine reuptake inhibitor (SDRI) |
SVN-015 is a serotonin–dopamine reuptake inhibitor (SDRI) which is under development for the treatment of major depressive disorder (MDD) and substance-related disorders such as stimulant use disorder.[1][2][3][4][5] It produces antidepressant-like effects in rodents similarly to the selective serotonin reuptake inhibitor (SSRI) fluoxetine.[4] SVN-015 is being developed by Solvonis Therapeutics, whose chief scientific officer (CSO) is David Nutt, in collaboration with the National Institute on Drug Abuse (NIDA).[1][2][3][4][6] As of August 2026, the drug is in the preclinical research stage of development for all indications.[1][2][3][5][7] The chemical structure of SVN-015 does not yet appear to have been disclosed.[1] However, Solvonis Therapeutics has patented monoamine transporter modulators.[8][9][10]
See also
[edit]References
[edit]- 1 2 3 4 5 "SVN 015". AdisInsight. 5 August 2026. Retrieved 6 August 2026.
- 1 2 3 "Delving into the Latest Updates on SVN-015 with Synapse". Synapse. 9 April 2026. Retrieved 6 August 2026.
- 1 2 3 Lyall I (6 August 2026). "US drug agency to fund further testing of Solvonis addiction candidate". Proactiveinvestors UK. Retrieved 6 August 2026.
- 1 2 3 "Expansion of SVN-015 into Depression Following Positive Preclinical Data". Investing News Network (INN). 28 January 2026. Retrieved 6 August 2026.
- 1 2 "SVN-015 Advances into Further NIDA-Funded Studies Following Encouraging Initial Screening". Investing News Network (INN). 6 August 2026. Retrieved 6 August 2026.
- ↑ "Psychedelic Companies Directory". Psychedelic Alpha. Psychedelic Alpha. 9 August 2024. Retrieved 6 August 2026.
- ↑ "Psychedelic Drug Development Tracker". Psychedelic Alpha. Psychedelic Alpha. Retrieved 6 August 2026.
- ↑ US 20240190809, Nutt D, Borthwick A, "Therapeutic aminoindane compounds and compositions", published 11 May 2022, assigned to Awakn Ls Europe Holdings Ltd
- ↑ WO 2023156565, Borthwick A, Micheli F, Micoli A, Palazzesi F, Cianciulli A, Tyacke R, Nutt D, "Bridged ring compounds and their therapeutic use as cns agents", published 16 February 2023, assigned to Awakn Ls Europe Holdings Ltd
- ↑ WO 2023139163, Nutt D, Borthwick A, Tyacke R, "1,3-benzodioxole esters and their therapeutic use", published 19 January 2023, assigned to Awakn Ls Europe Holdings Ltd
External links
[edit] | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |